BioAtla (BCAB) Other Non-Current Assets (2020 - 2026)
BioAtla (BCAB) posted quarterly Other Non-Current Assets of $163000.0 for Q1 2026, little changed quarter-over-quarter from $163000.0 in Q4 2025.
BioAtla (BCAB) Other Non-Current Assets (2020 - 2026) Analysis & Trends
BioAtla's Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $163000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets changed N/A year-over-year to $163000.0; the TTM figure through Mar 2026 stood at $163000.0 (changed N/A YoY), while the FY2025 annual figure was $163000.0, changed N/A from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $163000.0, roughly flat from $163000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $163000.0 in Q2 2025, with the low at $154000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $154000.0 (2022), against an average of $156846.2.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets climbed 0.65% in 2022, then dropped 0.65% in 2023.
- BioAtla's Other Non-Current Assets stood at $154000.0 in 2022, then changed by 0.0% to $154000.0 in 2023, then changed by 0.0% to $154000.0 in 2024, then rose by 5.84% to $163000.0 in 2025, then changed by 0.0% to $163000.0 in 2026.
- Business Quant data shows BCAB's Other Non-Current Assets at $163000.0 in Q1 2026, $163000.0 in Q4 2025, and $163000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | 163,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 163,000.00 |
| Mar 31, 2026 | 163,000.00 |
| Dec 31, 2025 | 163,000.00 |
| Sep 30, 2025 | 163,000.00 |
| Jun 30, 2025 | 163,000.00 |
| Mar 31, 2024 | 154,000.00 |
| Dec 31, 2023 | 154,000.00 |
| Sep 30, 2023 | 154,000.00 |
| Jun 30, 2023 | 154,000.00 |
| Mar 31, 2023 | 154,000.00 |
| Dec 31, 2022 | 154,000.00 |
| Sep 30, 2022 | 154,000.00 |
| Jun 30, 2022 | 155,000.00 |
| Mar 31, 2022 | 154,000.00 |
| Dec 31, 2021 | 154,000.00 |
| Sep 30, 2021 | 154,000.00 |
| Jun 30, 2021 | 154,000.00 |
| Mar 31, 2021 | 154,000.00 |
| Dec 31, 2020 | 154,000.00 |